Am J Health Syst Pharm. 2007;64(22):2335-2348. Obesity. No data on the pharmacokinetics of telavancin in obese patients are available. RYAN J. ATTWOOD, PHARM.D., is Postgraduate Year 1 Pharmacy ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

The manufacturer of telavancin has completed Phase III trials in patients with complicated skin and soft-tissue infections (the ATLAS I and II trials). A new drug application (NDA) was filed with ...